Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | The management of polycythemia vera with cytoreductive drug therapy

Tiziano Barbui • 22 Aug 2022
Texas MPN Workshop 2022
Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Hydroxyurea Interferon Ropeginterferon alfa-2b Ruxolitinib

In this video, Tiziano Barbui, MD, Bergamo Hospital Research Foundation, Bergamo, Italy, discusses the role of cytoreductive therapy in the management of patients with polycythemia vera (PV) who are at high risk for thrombosis, and further highlights other treatment approaches for these patients. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Tiziano Barbui

COVID-19 and MPNs: updates from the ELN study
Tiziano Barbui • 10 Nov 2022
10:20
New guidelines for the treatment and management of polycythemia vera
Tiziano Barbui • 6 Oct 2022
3:24
The impact of ruxolitinib on the long-term survival of patients with MF
Tiziano Barbui • 22 Aug 2022
6:00
COVID-19 and MPN updates
Tiziano Barbui • 22 Aug 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals